Recently, we identified that CD26 is uniformly and intensely expressed in osteoclasts, whereas its expression in the plasma cells of patients with multiple myeloma was heterogeneous, leading to marked differences of response to CD26mAb therapy in multiple myeloma (28, 29). This evidence concerns the gene DPP4 and AL amyloidosis.